8-K: Elicio Therapeutics Stockholders Elect Directors and Ratify Auditor at 2025 Annual Meeting

Elicio Therapeutics held its 2025 annual meeting where stockholders elected two directors and ratified the appointment of Baker Tilly US, LLP as the company's auditor.

Summary

• Elicio Therapeutics held its 2025 Annual Meeting of Stockholders on May 19, 2025.
• Stockholders voted on two proposals: electing two directors and ratifying the appointment of Baker Tilly US, LLP as the independent auditor for the fiscal year ending December 31, 2025.
• 70.1% of shares entitled to vote were represented at the meeting, constituting a quorum.
• Karen Wilson and Robert R. Ruffolo, Jr. were elected as directors to hold office until the 2028 annual meeting.
• The appointment of Baker Tilly US, LLP as the independent auditor for the fiscal year ending December 31, 2025 was ratified.

Sentiment

Score: 7

Explanation: The document reflects standard corporate governance procedures, indicating stability and adherence to regulatory requirements. The successful election of directors and ratification of the auditor are positive signs, but the document itself is routine.

Positives

• Both director nominees were successfully elected to the Board.
• The appointment of the independent auditor was successfully ratified.
• A quorum was achieved at the Annual Meeting, indicating sufficient shareholder participation.

Industry Context

This announcement is a routine part of corporate governance, ensuring compliance with regulations and shareholder representation.

Management Changes

Stakeholder Impact

• Shareholders have exercised their voting rights to elect directors and ratify the auditor.
• The election of directors ensures continued governance and oversight of the company.
• The ratification of the auditor provides assurance of financial statement integrity.

Key Dates

Keywords

Annual Meeting, Director Election, Auditor Ratification, Stockholders, Elicio Therapeutics, Governance